Stifel analyst Alex Thompson reiterated a Buy rating and $49.00 price target on Immunovant (NASDAQ: IMVT) following Q4 results and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE